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Reply to the Editor:
Dr Taheri made an important point in his
comment, which we probably should have
discussed in our article. However, first I, on
behalf of my coauthors, wish to clarify that
we did not inject “isogenic myofibril
grafts,” which would represent a differen-
tiated anatomic unit of a muscle tissue.
Instead, we transplanted either skeletal
myoblasts, which are immature progenitor
cells, or marrow stromal cells, which con-
tain a pluripotent cell population. Such im-
mature cells are able to migrate and self-
assemble with preexisting supracellular
structure, as we reported.
The hypothesis we postulated to explain
the mechanism of this phenomenon should
indeed predict that those donor cells, if
implanted as an isolated island within a
scar tissue, would lack the microenviron-
ment to allow them to integrate into the
preexisting native myocardial syncytium.
We and others have pointed out that how
such cells surrounded by scar contribute to
the myocardial function, as has been re-
ported experimentally and in some early
clinical trials, remains unclear at present.1
It is of some interest to recall how the
strategy of implanting cells into scar
started. In our studies in the early 1990s,2,3
which were the first attempts to use cell
therapy for myocardial regeneration, we
lacked the tools for cell labeling and thus
created a homogeneous scar induced by
cryoinjury. By implanting myoblasts
within such a scar, we were able to show
that the new myofibers surrounded by the
scar tissue originated from our donor cells.
Because turning noncontractile scar tissue
into potentially contractile muscle tissue is
an intuitively appealing idea, many inves-
tigators in the subsequent studies, both ex-
perimental and clinical, have continued to
use the model of implanting cells within
the scar tissue, even though there has been
no convincing evidence that these isolated
muscle fibers can actually contribute to the
synchronized contractile function of the
myocardium.
In studying the pathophysiologic roles
of marrow stromal cells, it has been shown
that tissue injuries, such as myocardial in-
farction, can send a signal to recruit mar-
row stromal cells from the bone marrow,
which traffic through the bloodstream to
target the infarcted segment of the myocar-
dium. There they undergo milieu-depen-
dent differentiation, expressing a number
of phenotypes.4 We have suggested that
some of these cells that reached the peri-
infarct zone became endothelial and vascu-
lar smooth muscle cells to participate in
vasculogenesis and enhance collateral cir-
culation. Some cells, which reached the
scar tissue through patent collateral ves-
sels, may express a myofibroblastic pheno-
type and participate in scar maturation to
reduce scar expansion and rupture. The
marrow cells in the peri-infarct zone that
are in contact with viable and contracting
host myofibers may differentiate into car-
diomyocytes and integrate into the existing
myofibers as we reported1, and this may
play a role in modulating the postinfarct
remodeling process of the ventricle. Yet
other mechanisms are possible. The neo-
cardiomyocytes, which have received phe-
notypic signals from native cardiomyo-
cytes at the peri-infarct zone, may then
migrate toward the myocardial scar to re-
duce infarct size. Various transforming
growth factors and cytokines coming from
the surrounding cells and extracellular matrix
may also play important roles, as suggested
by Dr Taheri. Clearly, much needs to be
learned, and from such understanding better
clinical strategies to use cell therapy for myo-
cardial injury may yet evolve in the future.
Ray C.-J. Chiu, MD, PhD
Senior author
McGill University
Montreal, Quebec, Canada
References
1. Chiu RC. Therapeutic cardiac angiogenesis
and myogenesis: The promises and chal-
lenges on a new frontier. J Thorac Cardio-
vasc Surg. 2001;122:851-2.
2. Marelli D, Desrosiers C, El-Alfy M, Kao RL,
Chiu RC. Cell transplantation for myocardial
repair: an experimental approach. Cell Trans-
plant. 1992;1:383-90.
3. Chiu RC, Zibaitis A, Kao RL. Cellular car-
diomyoplasty: myocardial regeneration with
satellite cell implantation. Ann Thorac Surg.
1995;60:12-8.
4. Bittira B, Shum-Tim D, Al-Khaldi A, Chiu
RC. Mobilization and homing of bone marrow
stromal cells in myocardial infarction. Eur
J Cardiothorac Surg. 2003;24:393-8.
doi:10.1016/j.jtcvs.2003.07.020
Asymptomatic mitral valve
incompetence: Is there evidence for
surgery?
To the Editor:
The article by David and colleagues1 in the
May 2003 issue of the Journal, “Late Out-
comes of Mitral Valve Repair for Floppy
Valves: Implications for Asymptomatic Pa-
tients,” stirs important unanswered ques-
tions and concerns. The conclusion that
patients with asymptomatic mitral valve in-
competence are candidates for surgery
might be extrapolative yet beneficial—if it
had stemmed from a different study design.
In statistical terms, significance for operat-
ing was clearly established; however, this
was more rhetorical than useful in clinical
practice. The following issues were not
mentioned in the discussion or among the
discussants.
First, asymptomatic simply means no
symptoms. Mitral valve surgery is feasible,
but its benefits to the individual patient
cannot be observed here because of the
confounding variables in the methodology
and results. To the reader, the concept of
cause and effect is paramount to executing
successful cardiovascular epidemiology.
Whereas the scientific sequence of cause
and effect is clear, the application of such a
valid concept in this article leans to the
reverse order. In other words, because sur-
gery in patients without symptoms had a
low morbidity and mortality (cause), it is
recommended to operate for asymptomatic
mitral incompetence (effect). Lowering the
threshold to operate must stem from con-
vincing data, and even if statistically sig-
nificant the clinical indication is neither
relative nor absolute. The patient’s physio-
logic status must the underlying cause for
an operation, and the outcome of the oper-
ation (effect) must treat that cause. In this
article despite the effect being feasible, the
cause is far from a true clinical indication.
The practicing surgeon can be confused
with the paradigm of cause and effect that
appears to argue that the mortality is higher
among patients with symptoms. Drawing
feasibility from such a statistic may intro-
duce a new “fuzzy logic” dimension that
has no order and no cause followed by
effect features.2 This logic results from
many decision-making and problem-solv-
ing tasks that are too complex to be under-
stood quantitatively; however, people suc-
ceed by using knowledge that is imprecise
rather than precise.
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